These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
419 related articles for article (PubMed ID: 17390075)
1. Distinct responses of two hepatocellular carcinoma cell lines of a similar origin to immunotherapies targeting regulatory or effector T cells. Nagayama Y; Hase W; Motoyoshi Y; Saitoh O; Sogawa R; Nakao K Oncol Rep; 2007 May; 17(5):1269-73. PubMed ID: 17390075 [TBL] [Abstract][Full Text] [Related]
2. GITR ligand-costimulation activates effector and regulatory functions of CD4+ T cells. Igarashi H; Cao Y; Iwai H; Piao J; Kamimura Y; Hashiguchi M; Amagasa T; Azuma M Biochem Biophys Res Commun; 2008 May; 369(4):1134-8. PubMed ID: 18346459 [TBL] [Abstract][Full Text] [Related]
3. Targeting acute allograft rejection by immunotherapy with ex vivo-expanded natural CD4+ CD25+ regulatory T cells. Xia G; He J; Zhang Z; Leventhal JR Transplantation; 2006 Dec; 82(12):1749-55. PubMed ID: 17198271 [TBL] [Abstract][Full Text] [Related]
4. In vivo expansion of CD4+Foxp3+ regulatory T cells mediated by GITR molecules. Nishioka T; Nishida E; Iida R; Morita A; Shimizu J Immunol Lett; 2008 Dec; 121(2):97-104. PubMed ID: 18930767 [TBL] [Abstract][Full Text] [Related]
5. Function of CD4+,CD25+ Treg cells in MRL/lpr mice is compromised by intrinsic defects in antigen-presenting cells and effector T cells. Parietti V; Monneaux F; Décossas M; Muller S Arthritis Rheum; 2008 Jun; 58(6):1751-61. PubMed ID: 18512811 [TBL] [Abstract][Full Text] [Related]
6. Reciprocal CD4+ T-cell balance of effector CD62Llow CD4+ and CD62LhighCD25+ CD4+ regulatory T cells in small cell lung cancer reflects disease stage. Koyama K; Kagamu H; Miura S; Hiura T; Miyabayashi T; Itoh R; Kuriyama H; Tanaka H; Tanaka J; Yoshizawa H; Nakata K; Gejyo F Clin Cancer Res; 2008 Nov; 14(21):6770-9. PubMed ID: 18980970 [TBL] [Abstract][Full Text] [Related]
8. Regulatory T cell-resistant CD8+ T cells induced by glucocorticoid-induced tumor necrosis factor receptor signaling. Nishikawa H; Kato T; Hirayama M; Orito Y; Sato E; Harada N; Gnjatic S; Old LJ; Shiku H Cancer Res; 2008 Jul; 68(14):5948-54. PubMed ID: 18632650 [TBL] [Abstract][Full Text] [Related]
9. Systemic anti-CD25 monoclonal antibody administration safely enhances immunity in murine glioma without eliminating regulatory T cells. Fecci PE; Sweeney AE; Grossi PM; Nair SK; Learn CA; Mitchell DA; Cui X; Cummings TJ; Bigner DD; Gilboa E; Sampson JH Clin Cancer Res; 2006 Jul; 12(14 Pt 1):4294-305. PubMed ID: 16857805 [TBL] [Abstract][Full Text] [Related]
10. In vivo depletion of CD4+FOXP3+ Treg cells by the PC61 anti-CD25 monoclonal antibody is mediated by FcgammaRIII+ phagocytes. Setiady YY; Coccia JA; Park PU Eur J Immunol; 2010 Mar; 40(3):780-6. PubMed ID: 20039297 [TBL] [Abstract][Full Text] [Related]
11. Increased CD4+CD25+Foxp3+ regulatory T cells in tolerance induced by portal venous injection. He F; Chen Z; Xu S; Cai M; Wu M; Li H; Chen X Surgery; 2009 Jun; 145(6):663-74. PubMed ID: 19486771 [TBL] [Abstract][Full Text] [Related]
12. CD25+ regulatory T cell inhibition enhances vaccine-induced immunity to neuroblastoma. Johnson BD; Jing W; Orentas RJ J Immunother; 2007; 30(2):203-14. PubMed ID: 17471167 [TBL] [Abstract][Full Text] [Related]
13. Combination of CTL-associated antigen-4 blockade and depletion of CD25 regulatory T cells enhance tumour immunity of dendritic cell-based vaccine in a mouse model of colon cancer. Saha A; Chatterjee SK Scand J Immunol; 2010 Feb; 71(2):70-82. PubMed ID: 20384858 [TBL] [Abstract][Full Text] [Related]
14. Targeting CD4+CD25+FoxP3+ regulatory T-cells for the augmentation of cancer immunotherapy. Schabowsky RH; Madireddi S; Sharma R; Yolcu ES; Shirwan H Curr Opin Investig Drugs; 2007 Dec; 8(12):1002-8. PubMed ID: 18058571 [TBL] [Abstract][Full Text] [Related]
15. Role of tumor endothelium in CD4+ CD25+ regulatory T cell infiltration of human pancreatic carcinoma. Nummer D; Suri-Payer E; Schmitz-Winnenthal H; Bonertz A; Galindo L; Antolovich D; Koch M; Büchler M; Weitz J; Schirrmacher V; Beckhove P J Natl Cancer Inst; 2007 Aug; 99(15):1188-99. PubMed ID: 17652277 [TBL] [Abstract][Full Text] [Related]
16. Two distinct mechanisms of augmented antitumor activity by modulation of immunostimulatory/inhibitory signals. Mitsui J; Nishikawa H; Muraoka D; Wang L; Noguchi T; Sato E; Kondo S; Allison JP; Sakaguchi S; Old LJ; Kato T; Shiku H Clin Cancer Res; 2010 May; 16(10):2781-91. PubMed ID: 20460483 [TBL] [Abstract][Full Text] [Related]
17. CD4+CD25+ regulatory T cells suppress tumor immunity but are sensitive to cyclophosphamide which allows immunotherapy of established tumors to be curative. Ghiringhelli F; Larmonier N; Schmitt E; Parcellier A; Cathelin D; Garrido C; Chauffert B; Solary E; Bonnotte B; Martin F Eur J Immunol; 2004 Feb; 34(2):336-44. PubMed ID: 14768038 [TBL] [Abstract][Full Text] [Related]
18. TGF-beta1 modulates Foxp3 expression and regulatory activity in distinct CD4+ T cell subsets. Pyzik M; Piccirillo CA J Leukoc Biol; 2007 Aug; 82(2):335-46. PubMed ID: 17475784 [TBL] [Abstract][Full Text] [Related]
19. Partial depletion of CD69low-expressing natural regulatory T cells with the anti-CD25 monoclonal antibody PC61. McNeill A; Spittle E; Bäckström BT Scand J Immunol; 2007 Jan; 65(1):63-9. PubMed ID: 17212768 [TBL] [Abstract][Full Text] [Related]
20. Tr1 and naturally occurring regulatory T cells induce IgG4 in B cells through GITR/GITR-L interaction, IL-10 and TGF-beta. Satoguina JS; Adjobimey T; Arndts K; Hoch J; Oldenburg J; Layland LE; Hoerauf A Eur J Immunol; 2008 Nov; 38(11):3101-13. PubMed ID: 18924213 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]